Non-small Cell Lung Cancer Clinical Trials in Shanghai, Shanghai Municipality
97 recruitingShanghai, Shanghai Municipality, China
Showing 1–20 of 97 trials
Recruiting
Phase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC600 enrolled225 locationsNCT06345729
Recruiting
Phase 3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
AbbVie698 enrolled317 locationsNCT04928846
Recruiting
Phase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-small Cell Lung Cancer (NSCLC)
Amgen750 enrolled383 locationsNCT05920356
Recruiting
Phase 1Phase 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366
Recruiting
Phase 1
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Metastatic Breast CancerHER2-negative Breast CancerAdvanced Solid Tumor+6 more
BeOne Medicines399 enrolled63 locationsNCT06120283
Recruiting
Phase 3
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Non-small Cell Lung Cancer
Summit Therapeutics780 enrolled202 locationsNCT06767514
Recruiting
Phase 1Phase 2
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Breast CancerNon-small Cell Lung CancerAdvanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.414 enrolled20 locationsNCT07169994
Recruiting
Phase 1Phase 2
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
Non-small Cell Lung Cancer (NSCLC)
Suzhou Suncadia Biopharmaceuticals Co., Ltd.400 enrolled1 locationNCT06754930
Recruiting
Phase 1Phase 2
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
Colorectal, CancerNon-small Cell Lung CancerKRAS P.G12C+1 more
Allist Pharmaceuticals, Inc.240 enrolled27 locationsNCT05288205
Recruiting
DREAM Study: DNA/RNA-NGS Co-Testing in Driver-Negative, Treatment-Resistant NSCLC
Non-small Cell Lung Cancer
Baohui Han508 enrolled1 locationNCT06846762
Recruiting
Not Applicable
GT201 Injection in Combination with Teraplizumab Injection for Treatment of Patients with Non-small Cell Lung Cancer
Non-small Cell Lung CancerAdult
Grit Biotechnology20 enrolled3 locationsNCT06235242
Recruiting
Phase 2
Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer
Non-small Cell Lung CancerAntineoplastic AgentsEGFR+5 more
Peng Zhang60 enrolled1 locationNCT06755684
Recruiting
Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer
Non-small Cell Lung Cancer
Shanghai Chest Hospital250 enrolled1 locationNCT06730503
Recruiting
Phase 2
A Phase 2 Clinical Study of ABSK061 and ABSK043
Urothelial CarcinomaSolid TumorsNon-small Cell Lung Cancer+1 more
Abbisko Therapeutics Co, Ltd202 enrolled21 locationsNCT06632262
Recruiting
Phase 1
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
Colorectal, CancerPancreatic CancerNon-small Cell Lung Cancer+1 more
Qilu Pharmaceutical Co., Ltd.250 enrolled5 locationsNCT06403735
Recruiting
Phase 2
Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer
Advanced Non-Small Cell Lung Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd54 enrolled6 locationsNCT05420220
Recruiting
Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC
Non-small Cell Lung CancerNeuroendocrine CarcinomaHistology Transformation
Fudan University50 enrolled1 locationNCT06369181
Recruiting
Phase 3
SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations
Non-small Cell Lung Cancer
Nanjing Sanhome Pharmaceutical, Co., Ltd.242 enrolled1 locationNCT06080776
Recruiting
Phase 3
Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC
Non-small Cell Lung Cancer
Shouyao Holdings (Beijing) Co. LTD120 enrolled1 locationNCT06031558
Recruiting
Phase 2
Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors
Breast CancerProstate CancerNon-small Cell Lung Cancer
RenJi Hospital100 enrolled1 locationNCT03392233